Biopharmaceutical company ADMA Biologics Inc (NASDAQ:ADMA) has started collecting convalescent plasma from patients who have recovered after contracting the coronavirus.
The company revealed that it will collect the plasma through its subsidiary DMA BioCenters Georgia Inc. The biopharma specializes in the development of treatments by studying and deriving the healing properties from patients that have a high level of immunity. The treatment is then used to treat patients that have weakened immunity or those that highly susceptible to infections.
ADMA’s decision to start collecting plasma from people that have recovered from COVID-19, therefore, presents some hope for combatting the disease, which has turned into a global pandemic. Biopharma will use the plasma to produce immune globulin, which contains polyclonal antibodies that are effective at combatting infectious illnesses. The company is calling on people that have recovered from COVID-19 to donate their plasma.
“During this unprecedented time, ADMA has risen to the challenge of helping confront the growing coronavirus pandemic, while fulfilling our mission to help patients battle infectious diseases,” stated AMDA CEO Adam Grossman.
The CEO also noted that hyperimmune globulin and immune globulin could potentially provide a head start at treating COVID-19 patients. Grossman also pointed out that the key to achieving success with the immune globulin approach is to collect plasma with high antibody count from patients that have fully recovered after catching the coronavirus. ADMA is encouraging patients that have recovered and have not exhibited any symptoms for at least 14 days to contribute to the process.
There already exists an alliance of pharmaceutical companies that aim to use the plasma and immune globulin approach to create COVID-19 treatment. The alliance is known as the CoVIg-19 Plasma Alliance, and ADMA is already a member. The members of this alliance believe that their approach may provide a quick remedy to the situation.
More than 40 biopharmaceuticals have been developing a cure for the coronavirus, but the process is slow, and results are not yet favorable. If the plasma approach works, then it might provide a much-needed remedy.